Advertisement
Canada markets open in 58 minutes
  • S&P/TSX

    22,107.08
    +194.56 (+0.89%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CAD/USD

    0.7362
    -0.0010 (-0.14%)
     
  • CRUDE OIL

    82.60
    +1.25 (+1.54%)
     
  • Bitcoin CAD

    95,841.95
    +471.11 (+0.49%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,232.60
    +19.90 (+0.90%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,498.25
    -5.50 (-0.03%)
     
  • VOLATILITY

    13.02
    +0.24 (+1.88%)
     
  • FTSE

    7,952.37
    +20.39 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6817
    +0.0012 (+0.18%)
     

Valeant just got blindsided

Joe Papa
Joe Papa

(Joe Papa, CEO of Valeant.YouTube, The Street)

The last week or so was supposed to be one of tiny tidbits of happy news for Valeant Pharmaceuticals, but the company was just blindsided, as the Food and Drug Administration raised concerns about one of its drug candidates.

The drug in question is glaucoma treatment latanoprostene bunod, and its approval was supposed to be a walk.

Every analyst on Wall Street was thinking about it that way. Even Valeant bear David Maris of Wells Fargo had the approval of all of these new drugs modeled into his Valeant projections.

From Maris' note out this morning:

"This morning (7/22), Valeant announced that it has received a Complete Response Letter (CRL) from the FDA regarding its glaucoma product candidate latanoprostene bunod. The CRL sites concerns regarding manufacturing deficiencies pertaining to an inspection of a Bausch & Lomb manufacturing facility in Tampa, Florida. The CRL was unexpected and we had included latanoprostene bunod in our model with peak sales of $150 million in 2020."

ADVERTISEMENT

This interrupts what was supposed to be a schedule of approvals for the embattled pharmaceutical company, which has seen its stock plummet around 90% since October. That's when accusations from a short seller combined with government scrutiny over its pricing practices turned Wall Street against what was once one of its darlings.

Valeant got approval on two other drugs in the last few days. One was Relistor, an anticonstipation tablet that had no issue with approval.

The other was brodalumab, a new psoriasis drug that 14 of the 18 members on the FDA's advisory panel actually decided to "approve ... but only if certain risk management options for suicidal ideation and behavior (SIB) beyond labeling are implemented."

Valeant's stock is down slightly more than 6% on this news.

valeant stock chart
valeant stock chart

(Yahoo Finance)

NOW WATCH: Here's what you get when you order 'Omaha Steaks' in the mail



More From Business Insider